Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| BIOGEN INC.BIIB · Entity 1675 | EVP & Chief Financial Officer | February 12, 2020 | February 14, 2020 |
| Decoy Therapeutics Inc.FLKS · Entity 937 | Director | July 26, 2017 | July 27, 2017 |
| NEOGEN CORPNEOG · Entity 4338 | Director | October 01, 2026 | October 02, 2026 |
| Tempest Therapeutics, Inc.OVAS · Entity 7734 | Director | July 04, 2018 | July 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 10,865 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 10,865 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
BIOGEN INC.
Report date February 12, 2020 · Filed February 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,118 |
Ending reported balance
After 2020-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-12 · Exercise / conversion · Acquired 1,919 · Balance 3,732 Row 2 · 2020-02-12 · Tax withholding · Disposed 614 · Balance 3,118 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-02-12 | Direct | 10,550 |
Reported balance
After 2020-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-12 · Grant · Acquired 10,550 · Balance 10,550 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-12 | Direct | 10,601 |
Reported balance
After 2020-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-12 · Exercise / conversion · Disposed 1,919 · Balance 10,601 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-12 | Direct | 8,348 |
Reported balance
After 2020-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-12 · Other · Disposed 2,253 · Balance 8,348 F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Decoy Therapeutics Inc.
Report date July 26, 2017 · Filed July 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2027-07-26 | Direct | 12,000 |
Reported balance
After 2017-07-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-26 · Grant · Acquired 12,000 · Balance 12,000 F1: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017.
NEOGEN CORP
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 42,306 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 9,804 · Balance 42,306 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 · Expires 2036-10-01 | Direct | 20,558 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Grant · Acquired 20,558 · Balance 20,558 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants
Tempest Therapeutics, Inc.
Report date July 04, 2018 · Filed July 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2028-07-04 | Direct | 12,000 |
Reported balance
After 2018-07-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-04 · Grant · Acquired 12,000 · Balance 12,000 F1: The stock option will vest in twelve equal monthly installments at the end of each successive month following July 4, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in twelve equal monthly installments at the end of each successive month following July 4, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2019 Filed Jan 4, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,331 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001282 · form4.xml · derivative · entry 3 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,649 Underlying: Common Stock · 1,331 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 414 | $304.69 | $126,141.66 |
DisclosureSEC source: 0001127602-19-001282 · form4.xml · nonDerivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 917 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001282 · form4.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 04, 2018 Filed Jul 6, 2018 22:32 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001179110-18-009533 · edgar.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-07-04 F1 · derivative.exercise_date: The stock option will vest in twelve equal monthly installments at the end of each successive month following July 4, 2018. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:32 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantPerformance Stock Unit · Derivative | 5,390 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-001115 · form4.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,390 Underlying: Common Stock · 5,390 shares Expires not disclosed F2 · shares: The number of performance stock units ("PSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. The actual number of PSUs that will vest will be determined based upon achievement of three-year performance goals adopted by the Compensation and Management Development Committee of the Board of Directors (the "Committee") in the first quarter of 2018. F3 · derivative.exercise_date: All eligible PSUs will vest on the later of January 2, 2021 or the date of the Committee's determination of the degree to which the annual performance goals have been satisfied. F3 · derivative.expiration_date: All eligible PSUs will vest on the later of January 2, 2021 or the date of the Committee's determination of the degree to which the annual performance goals have been satisfied. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:32 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 8,980 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-001115 · form4.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,980 Underlying: Common Stock · 8,980 shares Expires 2021-01-02 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| July 26, 2017 Filed Jul 27, 2017 12:49 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001615219-17-000049 · wf-form4_150115975112524.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-07-26 F1 · derivative.exercise_date: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017. Read SEC document |
| June 21, 2017 Filed Jun 24, 2017 00:56 UTC | Tempest Therapeutics, Inc. OVAS · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001179110-17-009555 · edgar.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option will vest in twelve equal monthly installments at the end of each successive month following June 21, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.